Lower price overseas, in some cases much less. Deal structures are usually 20% - 25% of sales (although with our large array of indications we might get 35% - 40%). This is offset by the larger patient population.

When I switched over to investing in biopharma I looked at a bunch of examples and doubling U.S. revenue would give you a rough ballpark figure for total revenue, although a bit on the low side.